Scholar Rock Holding (SRRK) Net Cash Flow (2017 - 2026)
Scholar Rock Holding (SRRK) recorded quarterly Net Cash Flow of $106.4 million in Q1 2026, up 189.32% quarter-over-quarter from $36.8 million in Q4 2025, and up 366.19% on a YoY basis from $22.8 million in Q1 2025.
Scholar Rock Holding (SRRK) Net Cash Flow (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Net Cash Flow history runs 10 years deep, the most recent figure standing at $106.4 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 366.19% year-over-year to $106.4 million; the TTM figure through Mar 2026 stood at $293.4 million (up 538.46% YoY), while the FY2025 annual figure was $147.1 million, up 93.43% from the prior year.
- Net Cash Flow was $106.4 million for Q1 2026 at Scholar Rock Holding, up from $36.8 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $205.6 million in Q2 2022 to a low of -$172.7 million in Q3 2022.
- Historically, Net Cash Flow has averaged $12.8 million across 5 years, with a median of $1.4 million in 2024.
- The sharpest annual moves came in 2022 and 2025: Net Cash Flow tumbled 8912.8% in 2022, then jumped 976.74% in 2025.
- A 5-year view of Net Cash Flow shows it stood at -$29.8 million in 2022, then jumped by 214.27% to $34.1 million in 2023, then surged by 198.04% to $101.5 million in 2024, then slumped by 63.78% to $36.8 million in 2025, then jumped by 189.32% to $106.4 million in 2026.
- The last three Net Cash Flow figures came in at $106.4 million (Q1 2026), $36.8 million (Q4 2025), and $135.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.44 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 625.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.44 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 457.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 664,983.53 |
| 10 | Scholar Rock Holding | 6.03 Bn | 5.55 Bn | - | 106.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 106.35 Mn |
| Mar 31, 2026 | 106.35 Mn |
| Dec 31, 2025 | 36.76 Mn |
| Dec 31, 2025 | 36.76 Mn |
| Sep 30, 2025 | 135.25 Mn |
| Sep 30, 2025 | 135.25 Mn |
| Jun 30, 2025 | 15.00 Mn |
| Jun 30, 2025 | 15.00 Mn |
| Mar 31, 2025 | -39.95 Mn |
| Mar 31, 2025 | -39.95 Mn |
| Dec 31, 2024 | 101.49 Mn |
| Dec 31, 2024 | 101.49 Mn |
| Sep 30, 2024 | -16.98 Mn |
| Sep 30, 2024 | -16.98 Mn |
| Jun 30, 2024 | 1.39 Mn |
| Jun 30, 2024 | 1.39 Mn |
| Mar 31, 2024 | -9.88 Mn |
| Mar 31, 2024 | -9.88 Mn |
| Dec 31, 2023 | 34.05 Mn |
| Dec 31, 2023 | 34.05 Mn |